Genetron Takes Advantage of Fosun Sales Network; HCCscreen Gets Praise

Genetron celebrates a commercialization deal with Fosun Pharma while its flagship product HCCsreen is well-received in an influential peer-reviewed medical journal.
Oct. 29, 2021 05:20
Genetron Takes Advantage of Fosun Sales Network; HCCscreen Gets Praise

Genetron Health (Nasdaq: GTH) announced two major developments in the past week. The company has formed an exclusive partnership with pharmaceutical company Jiangsu Fosun Pharma (HKEX: 2196), and its early liver cancer screening product was well-received by medical expert organizations as published in the October 2021 issue of the Chinese Journal of Hepatology, a prestigious and influential journal in China.

Exclusive Commercialization Push

Under the Fosun Pharma partnership, the two will work to commercialize Genetron Health's product Seq-MRD. Seq-MRD, a clinical diagnostic tool that assesses treatment effectiveness, provides ultra-sensitive monitoring and guides therapy maintenance intensity for patients with select hematologic cancers. The companies plan to serve patients with lymphoid malignancies including acute lymphoblastic leukemia, multiple myeloma, and chronic lymphoid leukemia.

Genetron Health is a leading precision oncology company in China that focuses on molecular profiling tests, early cancer screening products and companion diagnostics development. The company's services cover all aspects of cancer treatment, and it also partners with global biopharmaceutical companies and offers customized services and products. The partnership marks Genetron Health's first MRD product released in the China market.

Fosun Pharma has a sales force of around 1,500 representatives for innovative drugs that target hematologic and lymphoid malignancies, solid tumors, and others. As a leading company, it operates in several aspects of the pharmaceutical and health industry including manufacturing and healthcare services. Fosun focuses on major therapeutic areas like oncology, immunology, "4 hypers" (hypertension, hyperlipidemia, hyperglycemia, and hyperuricemia), and the central nervous system. The company is also looking at new technologies such as targeted protein degradation, RNA, oncolytic virus, and gene therapy.

As part of their agreement, Genetron Health and Fosun Pharma will exclusively work together to promote and market Seq-MRD in hematologic-focused hospitals and clinics across designated territories in China. Fosun Pharma will leverage its staff of experienced sales representatives and its relationships with clinics, hospitals, and distributors while Genetron Health will provide technical and commercial support to the partnership.

China has a big market potential for MRD in hematologic cancers because of their prevalence. According to Global Health Data Exchange, in 2017, it was estimated that there were approximately 135,000 newly diagnosed patients with T- or B-cell lymphoid malignancies.  In terms of prevalence, the total number of patients in these cancers were approximately two to four times of the newly diagnosed numbers.

HCCscreen™ Noted in Peer-reviewed Medical Journal

Genetron Health's clinical results and technology findings of its early liver cancer screening product for hepatocellular carcinoma (HCC), HCCscreen™, were included in the October 2021 publication of Chinese Journal of Hepatology and well-received by medical experts.

Two articles in the October issue, authored and reviewed by around 50 top experts in China and submitted by the Infectious Disease Prevention and Control Division of the Chinese Preventive Medicine Association (CPMA) and the Chinese Foundation for Hepatitis Prevention and Control (CFHPC) noted Genetron's flagship HCCscreen.

Last year, HCCscreen was granted breakthrough device designation by the U.S. Food and Drug Administration. Now, experts in China reached consensus that the data from Genetron's HCCscreen study showed better screening performance compared to existing options. The article by suggested that HCCscreen's multi-omics strategy could be a better approach versus current methods.

The articles included the findings of 1,615 patient HIT study of Genetron Health's ctDNA-based technology approach, which combines methylation, mutation, and protein markers for HCC in its assay.

"We are excited that our innovative approach and prospective study results of HCCscreen were well-received by leading industry experts," Sizhen Wang, Genetron Health's co-founder and CEO, said about the articles.

The journal was established in 1993 under the Chinese Medical Association (CMA) and includes research on a wide variety of medical topics including the treatment and prevention of various liver diseases. The publication is highly influential on clinical practices among physicians in the liver disease medical community in China.

CapitalWatch Disclaimer 

All information contained herein as well as on the CapitalWatch website is obtained from sources believed to be reliable but not guaranteed to be accurate or all-inclusive. All material is for informational purposes only, is only the opinion of CapitalWatch and should not be construed as an offer or solicitation to buy or sell securities. The information includes certain forward-looking statements, which may be affected by unforeseen circumstances and/or certain risks. This report is not without bias. CapitalWatch received remuneration for this report. Please consult an investment professional before investing in anything viewed within.